ACM
RNAM

Asymmetry Capital Management’s Avidity Biosciences RNAM Stock Holding History

Asymmetry Capital Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-126,116
Closed -$3.11M – 36
2021
Q3 		$3.11M Buy
+126,116
New +$2.74M 1.87% 21

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Asymmetry Capital Management's RNAM Position: Q4 2021 in Review

Asymmetry Capital Management sold out of Avidity Biosciences (RNAM) in Q4 2021, closing a stake of 126,116 shares — an estimated $3.11M sold.

Asymmetry Capital Management first reported a position in RNAM in Q3 2021 and held it in 1 quarter. The position peaked at $3.11M in Q3 2021. 107 funds tracked by Wall St. Rank hold RNAM as of Q4 2021.

  • Asymmetry Capital Management reported no remaining Avidity Biosciences position as of Q4 2021 after selling out during the quarter.
  • Asymmetry Capital Management sold 126,116 Avidity Biosciences shares in Q4 2021, an estimated $3.11M.
  • Asymmetry Capital Management first reported a position in Avidity Biosciences in Q3 2021 and held it in 1 quarter.
  • Asymmetry Capital Management's Avidity Biosciences position peaked at $3.11M in Q3 2021.
  • 107 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2021.

Based on Asymmetry Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.